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Abstract
A greater understanding of the pathogenic mechanisms underpinning hypertrophic
cardiomyopathy (HCM) has translated to improved medical care and better survival
of affected individuals. Historically these patients were considered to be at high risk
of sudden cardiac death (SCD) during exercise; therefore, exercise recommendations
were highly conservative and promoted a sedentary life style. There is emerging evi-
dence that suggests that exercise in HCM has a favorable effect on cardiovascular
remodeling and moderate exercise programs have not raised any safety concerns.
Furthermore, individuals with HCM have a similar burden of atherosclerotic risk fac-
tors as the general population in whom exercise has been associated with a reduction
in myocardial infarction, stroke, and heart failure, especially among those with a high-
risk burden. Small studies revealed that athletes who choose to continue with regular
competition do not demonstrate adverse outcomes when compared to those who
discontinue sport, and active individuals implanted with an implantable cardioverter
defibrillator do not have an increased risk of appropriate shocks or other adverse
events. The recently published exercise recommendations from the European Associ-
ation for Preventative Cardiology account for more contemporary evidence and
adopt a more liberal stance regarding competitive and high intensity sport in individ-
uals with low-risk HCM. This review addresses the issue of exercise in individuals
with HCM, and explores current evidence supporting safety of exercise in HCM,
potential caveats, and areas of further research.
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1 | INTRODUCTION
The benefits of exercise on cardiovascular health and all-cause mortal-
ity are well established.1-9 However, studies have demonstrated a
nearly threefold increased risk of sudden cardiac death (SCD) in young
athletes with underlying cardiovascular conditions when compared to
sedentary individuals.10 Hypertrophic cardiomyopathy (HCM), first
described by Teare11 is a genetic disorder, characterized by the
presence of increased left ventricular wall thickness (≥15 mm) that is
not solely explained by abnormal loading conditions.12 Historically,
HCM was considered to be the leading cause of SCD in athletes.13-15
International recommendations therefore stood firm on the exclusion
of athletes with HCM from most competitive sports.16,17 Although
scientific bodies approach the issue of participation of nonathletic
patients with HCM in recreational sport in a more liberal fashion,
guidance regarding safe levels of exercise remains vague.18
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Consequently, patients adopt a sedentary lifestyle, with significant
impact on their physical and psychological well-being.19-26
HCM is the most common ICC encountered in clinical practice
and is thought to affect around 1 in 500 adults.27-30 Recent data
suggest that the prevalence may even be as high as 1 in 200.31
Extrapolating such figures indicate that approximately 120 000
people in the United Kingdom and 20 million people worldwide are
affected,32 representing a significant global burden.33 The imple-
mentation of primary and secondary preventative strategies;
preparticipation screening,34-37 mandated familial evaluation fol-
lowing SCD or diagnosis of ICC in a family,38 education around
cardiopulmonary resuscitation and automated external defibrilla-
tors39,40 have resulted in an expansion of the HCM population.
Furthermore, advances in management such as implantable car-
dioverter defibrillator (ICD) implantation have led to a reduction in mor-
tality.41 As a result, HCM mortality rates are now comparable to the
general population.42 Consequently, the need to reduce cardiovascular
risk over a normal lifespan becomes a priority in these individuals.
The risk of SCD during exercise in individuals with HCM, may not
be as high as initially perceived. Recent postmortem studies have
demonstrated that HCM accounts for a much smaller proportion of
SCD in athletic individuals.43,44 Moreover, recent studies of cardiac
rehabilitation programs in older patients with HCM in their sixth
decade of life, suggest that exercise in moderation may be safe.45,46
Murine models and clinical studies in athletes with HCM suggest that
exercise may even lead to favorable cardiac remodeling.47,48 In a small
study of lifelong competitive athletes with HCM there was no differ-
ence in terms of outcomes in athletes who adopted a more sedentary
lifestyle compared to those who continued competitive sport.49 The
shifting opinion regarding safety of exercise in HCM is reflected in the
most recent European Association of Preventative Cardiology (EAPC)
guidelines which support a more liberal approach towards sports par-
ticipation in low risk individuals with HCM.50 Figure 1 demonstrates
the evolution in exercise recommendations from the European Soci-
ety of Cardiology (ESC) and American Heart Association/American
College of Cardiology (AHA/ACC) alongside key contributory studies
of exercise in HCM. There still, however, remains intense debate
among specialists as to whether the pendulum has now swung too far
in the other direction.
1.1 | SCD and HCM
Although the benefits of exercise are compelling, SCD is the leading
medical cause of death in athletes.10,13,14,51 The incidence is between
1 and 2 per 100 000 person years10,13,14,51-53 and may be as high as
6.8 per 100 000 person years among adolescent athletes.54 Maron
et al demonstrated that HCM was the leading cause of SCD in US ath-
letes accounting for up to 36% of deaths.13-15 In a prospective cohort
study of SCD in young individuals in the Veneto region of Italy the
incidence of SCD was 2.3 per 100 000 per year in athletes compared
to 0.9 per 100 000 per year in nonathletes. The higher risk of sudden
F IGURE 1 Key studies of exercise in HCM and the resultant evolution of exercise recommendations
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death in athletes was attributable to underlying cardiovascular condi-
tions, therefore suggesting a 2.8-fold increased risk in athletes with a
predisposing cardiac pathology.10 These studies have largely formed
the basis for conservative exercise recommendations in individuals
harboring serious cardiac conditions such as HCM. The 2005 ESC
guidelines16 and the 2015 AHA guidelines17 restrict those individuals
with a definite diagnosis of HCM from competitive sport with the
exception of low intensity sports (bowling, billiards, curling, riflery, and
golf). Although the same scientific bodies approach the issue of partic-
ipation of HCM patients in recreational sport in a more moderate
way, the guidance regarding the intensity of exercise is vague.18
1.2 | The impact of conservatism
Results from the Italian data55 have been presumptively extrapolated
to all ICC and all levels of exercise. As a result, physicians often
encourage patients to adopt a sedentary lifestyle or provide vague
and impractical advice with regards to exercise.21,23 This practice is
compounded by the paucity of data relating to the beneficial effects
in this subset of patients with ICC and most importantly, the safety of
a structured exercise program. Presently, 55% of patients fail to meet
the minimum physical activity recommendations.19,20 A sedentary life-
style cultivates obesity and increases cardiovascular risk. In large
cohort studies, up to 70% of individuals with HCM were found to be
preobese or obese.26 Obesity in HCM leads to a significant increase in
left ventricular mass, obstructive physiology, worsening heart failure
symptoms as well as an increased likelihood of atrial fibrillation when
compared to nonobese individuals.25,26 Moreover, a sedentary life-
style promotes the development of additional risk factors for athero-
sclerosis and coronary artery disease (CAD), both associated with
excess mortality. In a cohort of 425 patients with HCM, hypertension
was present in 58% of black patients and 32% of white patients, and
was an independent risk factor (HR 2.02, 95% CI 1.05 to 3.88,
P = .036) for a composite outcome of cardiovascular death, cardiac
arrest or appropriate ICD therapy.56 Sorajja et al demonstrated that
individuals with HCM and severe CAD were at greater risk of death,
compared to those with mild to moderate or no CAD, and their risk
far exceeded historical death rates of CAD patients with normal left
ventricular function.24 Additionally, the psychological impact of a diag-
nosis of HCM should not be underestimated. In both competitive, as
well as recreational sportsmen and women, sport restrictions can lead
to anxiety and significantly worsen social functioning and stress
management.19,21-23
1.3 | Are we overestimating the risk?
The risk of SCD during exercise in HCM may not be as high as initially
thought. Although, Maron et al cited HCM as the most common cause
of cardiovascular death in athletes,13-15 other studies have shown
contrary evidence. Contemporaneous reports from Italy demonstrated
that coronary artery anomalies, arrhythmogenic right ventricular
cardiomyopathy (ARVC), and premature cardiovascular disease were
the most common causes of SCD.10 In a study of consecutive cases of
athletes referred to a national center for cardiovascular pathology43
sudden arrhythmic death syndrome was the most common cause of
death, in 42% of cases, while HCM contributed to only 6% of the
deaths. Similar findings have been reported in unselected cohorts of
U.S. collegiate athletes and young sudden deaths in Australia.44,53 In
addition, the association between HCM and SCD during exertion is
based predominantly on circumstantial evidence and contrasts to the
mounting evidence of adverse outcomes in individuals with ARVC/
carriers who participate in regular moderate or intense exercise.57,58
One, however, should exercise caution as we lack risk stratification
protocols for HCM in athletes and extrapolating data from predomi-
nantly sedentary cohorts may underestimate the risk. In a large study
of adolescent football players who underwent cardiac screening, three
of the eight deaths were due to HCM, two of whom had been identi-
fied during screening and continued to exercise.54
1.4 | Potential beneficial effects of exercise in
hypertrophy cardiomyopathy
Physical inactivity may exacerbate pathological processes already limit-
ing exercise capacity. Exercise intolerance in individuals with HCM is
mediated by a number of factors. These include a predisposition to
arrhythmias including atrial fibrillation (AF)59,60 and exercise-induced
arrhythmias.61 Pathological structural and vascular changes in the heart
may give rise to myocardial ischaemia,62 diastolic dysfunction63,64 and
left ventricular outflow tract obstruction.65 Individuals may demon-
strate an inability to respond to increases in activity due to an abnormal
blood pressure response66 and/or chronotropic incompetence.67
Peripheral deconditioning is also a major contributor to reduced exer-
cise tolerance. Exercise may help offset some of these limiting factors.
In patients with HF, improvements in exercise capacity have been
attributed to peripheral adaptation, including reduction in endothelial
dysfunction in the skeletal muscle vasculature as well as increased oxi-
dative capacity.68,69 Exercise may also increase stroke volume and
favorably remodel cardiac dimensions.70 Exercise interventions have
demonstrated beneficial outcomes in patients with HF71,72 reducing
mortality and hospital admissions. Exercise may also exert a beneficial
effect on diastolic filling and improve exercise capacity in patients with
HF with preserved ejection fraction.72 The effects on diastology sug-
gest that exercise may benefit individuals with established HCM in
whom diastolic dysfunction is a significant contributor to exercise limi-
tation. This notion is supported by a study in 106 athletes with HCM
which showed that athletes exhibited normal or supranormal indices of
diastolic function when compared to sedentary patients.47 Moreover,
experimental studies in murine models of HCM demonstrate that exer-
cise may halt or even reverse the cardiomyopathic process.48 Mice
with HCM initiated exercise, in a voluntary cage wheel, at either 2 or
6 months. Pathological evaluation at 8 months of those who began
exercising prior to disease expression, demonstrated inhibition of myo-
cardial fibrosis and disarray, whereas older mice showed only reversal
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of disarray. Exercise also prevented the induction of hypertrophic
markers and favorably affected apoptotic pathways in both groups.
Notably, there was no difference in mortality between mice with HCM
and non-transgenic mice.
1.5 | Cardiac rehabilitation in the general HCM
population
Two studies in HCM patients suggest that exercise may improve fit-
ness without a concomitant increase in arrhythmic burden. In a pro-
spective nonrandomized study of 20 symptomatic patients (mean
age 62 years), exercise intensity was increased from 50% to 85% of
an individual's heart rate reserve (HRR). Functional capacity,
assessed by a graded exercise test, improved from 4.7 to 7.2 METS
(P = .01). NYHA functional class also improved from baseline by ≥1
grade in 10 patients (50%).45 The most recent randomized controlled
trial, RESET-HCM,46 assigned patients (mean age 50 years) to
16 weeks of an unsupervised home-based moderate-intensity exer-
cise training program (n = 67) or usual activity (n = 69). Exercise
intensity in the intervention group increased from 60% to 70% of
the HRR. Mean peak oxygen consumption improved significantly
(P = .02) in the exercise training group. There were no adverse
events in either study. These studies demonstrate that exercise ben-
efits the cardiovascular fitness of HCM patients and may be safer
than initially anticipated.
It is important to note that these studies were not powered for
safety. In the RESET-HCM trial, although there was no death, aborted
SCD, ICD shocks, or sustained ventricular tachycardia (VT), the
authors reported that several participants experienced symptomatic
nonsustained VT (NSVT). One patient who had previously had NSVT,
experienced a further 30 s before starting the exercise program, while
another patient (who had an ICD) demonstrated an increase in burden
of symptomatic NSVT. A third patient experienced NSVT de novo
1 hour after exercising. All three individuals were withdrawn from the
study. Although occurrence of nonfatal arrhythmias was not signifi-
cantly different between groups, these episodes of symptomatic
arrhythmia warranted ICD implantation, and raised concerns of fur-
ther adverse events with continuation of exercise. With this in mind,
careful consideration should be given to an individual's SCD risk score
prior to provision of exercise recommendations. This also highlights
the importance of careful monitoring of these individuals. Further
work is needed in larger cohorts and younger age groups with the
adoption of more vigorous exercise regimes.
1.6 | Athletes with HCM
The recent position statement from the Sport Cardiology Section of
EAPC recommends that participation in intense exercise or competi-
tive sport may be considered after comprehensive clinical evaluation
in asymptomatic adults, with low ESC-SCD risk score and a mild HCM
phenotype.
This excludes those sports where syncope may cause harm or
death.50 These changing opinions are particularly pertinent to those
individuals who continue to compete or exercise above recommenda-
tions provided by their physicians.73 Data supporting the change in
recommendations stem from the clinical profiling of athletes with
HCM who are capable of competing at an elite level. Sheikh et al com-
pared 106 elite athletes with HCM to 101 sedentary individuals with
HCM. Athletes demonstrated a milder phenotype with regard to LVH,
and a third demonstrated the apical variant of HCM, indicating a
lower risk of SCD.47 Retrospective data from competitive athletes
with HCM have also shown that higher levels of exercise may not sig-
nificantly increase the risk of adverse outcomes. Results from a multi-
national, prospective ICD registry of 440 athletes with cardiovascular
disease (17% with HCM), participating in high risk and organized
sports, demonstrated no deaths related to arrhythmia, no aborted
SCD or injury following syncope or shock during sport, during
44 months follow-up period.74 In the original registry athletes with
HCM demonstrated the lowest number of VT/VF shocks during com-
petition/practice n = 1 (2%), in clear contrast to ARVC which was
associated with increased risk of ICD shock during competition or
practice.75
Pelliccia et al76 compared 15 athletes with HCM who continued
to engage in regular exercise or competitive sport to athletes who had
suspended exercise. Athletes had been engaged in sporting activities
for a mean of 15 ± 8 years at a level equivalent to regional or above.
Only two of these individuals were deemed to be high risk according
to the ESC SCD risk calculator, two were intermediate risk and the
remainder were low risk. None of these individuals had an ICD. Over
the course of 9 ± 6 years of follow-up only an amateur tennis player
suffered a cardiac arrest while walking. In terms of symptoms seven
individuals experienced these, the most significant being syncope
(n = 3). The event and symptom rate were not significantly different
between the two groups.
Although Pelliccia's group76 present optimistic findings there are
several issues to be mindful of. We know that the risk of SCD is
influenced by an athlete's demographics and sporting discipline.
Higher risk individuals include males, adolescents, black athletes, and
those competing in high intensity start-stop sports such as football
and basketball.13-15,54 In this study, the majority of these athletes
were male and Caucasian, therefore the results do not account for
ethnic variation in SCD. The sample size was small, with relatively
short follow-up and therefore not powered to detect a significant dif-
ference in outcomes, particularly given the low-event rate of SCD.
Additionally, the population may not reflect the consideration that
should be given to risk according to age. This was highlighted in a
recent study of outcomes in competitive adolescent football players
who underwent cardiac screening.54 Of the eight SCDs recorded,
three were due to HCM, of which two had been identified and were
advised not to continue playing competitively.
These findings highlight that estimation of the risk of an event is
not an easy task. Although the great majority of individuals with HCM
are expected to have a normal lifespan41,42 the risk of SCD appears to
vary with age. The highest risk is conferred to young individuals,77-79
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with a notable decrease in risk above the age of 60 years.80 In the
absence of previous hemodynamically compromising VT or ventricular
fibrillation, an individual's risk may be calculated using the ESC-SCD
risk score calculator.12 However, the timing of adverse events is not
predictable. The heterogeneity of outcomes is highlighted in studies
of ICD therapies. Maron et al81 demonstrated that the interval
between implantation and discharge varied widely, even by up to a
decade.82 In secondary prevention cases, individuals may not experi-
ence further events for up to 30 years.83 Longer term follow-up is
required and most importantly considerations such as age, gender,
ethnicity, sporting discipline, and ESC-SCD risk score should be fac-
tored into advice regarding an individual's exercise recommendations.
1.7 | Current practice and future perspectives
Based on the best available evidence, it seems reasonable to offer all
patients with HCM a comprehensive evaluation (Figure 2). This will
allow for a more individualized approach guided by the patient's risk,
symptoms, and baseline fitness. The exercise prescription should be
specific and abide by the “FITT” principle (frequency, intensity, time
[duration], type of exercise).84 Unless significant concerns exist, the
exercise prescription should satisfy current WHO recommendations
for physical activity.85 Maximal intensity should not exceed 70% of
HRR, which approximately equates to 80% of maximal predicted HR
or 14 to 16 of the Borg scale. Individuals at high risk of SCD, limited
by symptoms or with low baseline fitness should be optimized on
medical therapy and commenced at a lower exercise level which could
then be gradually increased based on their response. It seems
reasonable that for individuals who would qualify for competitive
sport, based on the Sport Cardiology Section of EAPC
recommendations,42 not to restrict the intensity level of recreational
exercise. For competitive athletes, recommendations should be
guided by the Sport Cardiology Section of EAPC recommendations.42
Ultimately, decisions relating to exercise prescription should take into
consideration the wishes of a well-informed patient.
Future research relating to competitive athletes should focus on
large, multicenter registries as the option of randomized studies does
not seem pragmatic. Large, randomized, multicenter studies, however,
are possible in the general HCM population and should explore bene-
fits and safety of different exercise regimes including higher intensity
programs and high intensity interval training, which are likely to be
more appealing to the expanding population of younger patients.
2 | CONCLUSION
It is clear that we are in the early stages of gathering data on safety of
exercise in HCM, but the advances in our understanding of the condi-
tion and its relation to exercise as a trigger of fatal arrhythmias should
not be ignored. Previous consensus guidelines regarding exercise pre-
scription were based on historical data and were overly restrictive.
The new guidelines propose a less restrictive approach, under specific
circumstances and after detailed discussion with the athlete and other
stakeholders. Although this is a welcomed perspective, one must
remain mindful that adequately powered, large cohort studies with
long-term follow-up are currently lacking. Therefore, at present, an
individualized rather than a one-size fits all approach is preferable.
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